Carboplatin and docetaxel in advanced non-small-cell lung cancer: results of a multicenter phase II study.

Background: To evaluate the efficacy of carboplatin and docetaxel combination in patients with advanced non-small-cell lung cancer.

Methods: In a phase II study, patients with inoperable stage IIIB or stage IV non-small-cell lung cancer (ECOG performance status of 0 or 1) were treated with the combination of carboplatin AUC 5 mg/ml.min and docetaxel 80 mg/m2 administered once every 3 weeks.